Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans.
Details
Serval ID
serval:BIB_F71F6A9EA243
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans.
Journal
NPJ vaccines
Working group(s)
NIAID HIV Vaccine Trials Network (HVTN) 076, 088, 086, 096, 097, 205 Study Teams
ISSN
2059-0105 (Electronic)
ISSN-L
2059-0105
Publication state
Published
Issued date
15/04/2021
Peer-reviewed
Oui
Volume
6
Number
1
Pages
56
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Publication Status: epublish
Abstract
We studied mucosal immune responses in six HIV-1 vaccine trials investigating different envelope (Env)-containing immunogens. Regimens were classified into four categories: DNA/vector, DNA/vector plus protein, protein alone, and vector alone. We measured HIV-1-specific IgG and IgA in secretions from cervical (n = 111) and rectal swabs (n = 154), saliva (n = 141), and seminal plasma (n = 124) and compared to corresponding blood levels. Protein-containing regimens had up to 100% response rates and the highest Env-specific IgG response rates. DNA/vector groups elicited mucosal Env-specific IgG response rates of up to 67% that varied across specimen types. Little to no mucosal IgA responses were observed. Overall, gp41- and gp140-specific antibodies dominated gp120 mucosal responses. In one trial, prior vaccination with a protein-containing immunogen maintained durability of cervical and rectal IgG for up to 17 years. Mucosal IgG responses were boosted after revaccination. These findings highlight a role for protein immunization in eliciting HIV-1-specific mucosal antibodies and the ability of HIV-1 vaccines to elicit durable HIV-1-specific mucosal IgG.
Pubmed
Web of science
Open Access
Yes
Create date
26/04/2021 13:18
Last modification date
08/08/2024 7:42